Beijing Beilu Pharmaceutical (300016) — Working Capital to Net Assets Ratio
Beijing Beilu Pharmaceutical (300016) has a Working Capital to Net Assets ratio of 31.1% as of September 2025. Working capital of CN¥736.08 Million (current assets of CN¥1.34 Billion minus current liabilities of CN¥603.04 Million) is measured against net assets of CN¥2.37 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Beijing Beilu Pharmaceutical's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Beijing Beilu Pharmaceutical Working Capital to Net Assets (2005–2024)
This chart shows how Beijing Beilu Pharmaceutical's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2005 to 2024. As of September 2025, the ratio stands at 31.1%, reflecting working capital of CN¥736.08 Million against net assets of CN¥2.37 Billion CNY. Check Beijing Beilu Pharmaceutical tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Beijing Beilu Pharmaceutical (2005–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Beijing Beilu Pharmaceutical from 2005 to 2024, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Beijing Beilu Pharmaceutical (300016) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 39.1% | CN¥715.95 Million | CN¥1.83 Billion | CN¥1.17 Billion | CN¥455.23 Million | ▼ -7.8 pp |
| 2023 | 46.9% | CN¥837.62 Million | CN¥1.79 Billion | CN¥1.20 Billion | CN¥359.17 Million | ▲ +1.4 pp |
| 2022 | 45.5% | CN¥875.34 Million | CN¥1.92 Billion | CN¥1.18 Billion | CN¥302.67 Million | ▼ -3.4 pp |
| 2021 | 49.0% | CN¥1.02 Billion | CN¥2.08 Billion | CN¥1.31 Billion | CN¥285.56 Million | ▼ -4.3 pp |
| 2020 | 53.2% | CN¥1.01 Billion | CN¥1.89 Billion | CN¥1.35 Billion | CN¥343.54 Million | ▲ +23.9 pp |
| 2019 | 29.3% | CN¥425.00 Million | CN¥1.45 Billion | CN¥550.89 Million | CN¥125.89 Million | ▼ -2.4 pp |
| 2018 | 31.7% | CN¥382.03 Million | CN¥1.21 Billion | CN¥444.17 Million | CN¥62.14 Million | ▼ -7.8 pp |
| 2017 | 39.5% | CN¥422.13 Million | CN¥1.07 Billion | CN¥471.35 Million | CN¥49.22 Million | ▼ -1.3 pp |
| 2016 | 40.8% | CN¥367.60 Million | CN¥901.69 Million | CN¥397.00 Million | CN¥29.40 Million | ▼ -9.6 pp |
| 2015 | 50.4% | CN¥469.84 Million | CN¥932.63 Million | CN¥547.98 Million | CN¥78.15 Million | ▲ +17.6 pp |
| 2014 | 32.8% | CN¥218.26 Million | CN¥666.33 Million | CN¥403.96 Million | CN¥185.70 Million | ▼ -36.4 pp |
| 2013 | 69.1% | CN¥386.72 Million | CN¥559.38 Million | CN¥415.51 Million | CN¥28.79 Million | ▼ -2.5 pp |
| 2012 | 71.7% | CN¥375.50 Million | CN¥523.96 Million | CN¥401.93 Million | CN¥26.44 Million | ▼ -9.2 pp |
| 2011 | 80.9% | CN¥397.40 Million | CN¥491.47 Million | CN¥416.35 Million | CN¥18.95 Million | ▲ +0.6 pp |
| 2010 | 80.3% | CN¥375.39 Million | CN¥467.62 Million | CN¥382.87 Million | CN¥7.49 Million | ▼ -9.8 pp |
| 2009 | 90.1% | CN¥390.60 Million | CN¥433.71 Million | CN¥408.21 Million | CN¥17.60 Million | ▲ +23.6 pp |
| 2008 | 66.4% | CN¥88.49 Million | CN¥133.23 Million | CN¥115.00 Million | CN¥26.52 Million | ▲ +17.0 pp |
| 2007 | 49.4% | CN¥44.60 Million | CN¥90.33 Million | CN¥94.25 Million | CN¥49.66 Million | ▲ +18.5 pp |
| 2006 | 30.8% | CN¥22.06 Million | CN¥71.59 Million | CN¥74.46 Million | CN¥52.40 Million | ▲ +13.2 pp |
| 2005 | 17.6% | CN¥11.40 Million | CN¥64.71 Million | CN¥52.45 Million | CN¥41.05 Million | — |